Pimavanserin 20 mg

DRUG2 trials

Sponsors

ACADIA Pharmaceuticals Inc.

Conditions

Agitation and Aggression in Alzheimer's DiseaseDementia-related Psychosis

Phase 2

Study to Examine the Safety and Efficacy of Pimavanserin for the Treatment of Agitation and Aggression in Alzheimer's Disease (SERENE)

TerminatedNCT02992132

ACADIA Pharmaceuticals Inc.Agitation and Aggression in Alzheimer's Disease

Start: 2016-11-30End: 2018-02-16Updated: 2019-03-28

Phase 3

Relapse Prevention Study of Pimavanserin in Dementia-related Psychosis

CompletedNCT03325556

ACADIA Pharmaceuticals Inc.Dementia-related Psychosis

Start: 2017-09-27End: 2019-10-30Updated: 2021-06-21

Related Papers

Safety and efficacy of pimavanserin in patients with Lewy body dementia experiencing dementia-related psychosis in the HARMONY study.

2025-11-24

Efficacy and safety of pimavanserin in patients with Alzheimer’s dementia psychosis in the HARMONY phase 3, randomized discontinuation study: a post hoc subgroup analysis

Alzheimer s & Dementia2022-12-011 citations

Motor- and cognition-related safety of pimavanserin in patients with Parkinson's disease psychosis

Frontiers in Neurology2022-10-0513 citations

Development and assessment of a brief screening tool for psychosis in dementia

Alzheimer s & Dementia2021-12-01

Trial of Pimavanserin in Dementia-Related Psychosis

New England Journal of Medicine2021-07-21126 citations

Development and assessment of a brief screening tool for psychosis in dementia

Alzheimer s & Dementia Diagnosis Assessment & Disease Monitoring2021-01-012 citations

HARMONY Study: Pimavanserin Significantly Prolongs Time to Relapse of Dementia-Related Psychosis

Innovation in Aging2020-12-014 citations

427 - HARMONY study: pimavanserin significantly reduces risk of relapse of dementia-related psychosis

International Psychogeriatrics2020-10-013 citations

Pimavanserin: A Novel Antipsychotic With Potentials to Address an Unmet Need of Older Adults With Dementia-Related Psychosis.

2020-02-2620 citations